Repligen to Acquire BioLife Solutions for $1.5B Amid Legal Scrutiny

Key Facts

1Repligen Corporation has agreed to acquire BioLife Solutions in a cash-and-stock deal valued at approximately $1.5 billion.

2A Lake Street analyst downgraded BioLife Solutions stock to 'Hold' with a price target of $31.00 following the merger news.

3Investor rights law firm Halper Sadeh LLC is investigating whether the acquisition price is fair to BioLife Solutions shareholders.

In a strategic move to expand its bioprocessing footprint within the cell and gene therapy industry, Repligen Corporation has announced an agreement to acquire BioLife Solutions. The deal is valued at approximately $1.5 billion and will be executed through a combination of cash and stock. According to reports, BioLife shareholders are set to receive $11.25 in cash and 0.1442 shares of Repligen for each share held.

Following the merger news, Lake Street analysts downgraded BioLife Solutions stock to a 'Hold' rating, setting a price target of $31.00. Simultaneously, the law firm Halper Sadeh LLC launched a legal investigation on behalf of investors to determine if the acquisition price is fair to the target company's shareholders. Per market data, BLFS closed at $29.09 while RGEN closed at $145.49 (close July 20, 2026).

Traders should watch BLFS price levels, which saw a day high of $29.45 and a low of $28.74 (close July 20, 2026). With no immediate sector-specific catalysts in the upcoming economic calendar, focus remains on any legal developments arising from shareholder rights investigations or updates regarding the merger's closing timeline.